Ivacaftor
- Generic Name
- Ivacaftor
- Brand Names
- Kalydeco, Orkambi, Symdeko, Trikafta (100 Mg / 50 Mg / 75 Mg; 150 Mg)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28N2O3
- CAS Number
- 873054-44-5
- Unique Ingredient Identifier
- 1Y740ILL1Z
- Background
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with o...
- Indication
When used as monotherapy as the product Kalydeco, ivacaftor is indicated for the treatment of cystic fibrosis (CF) in patients aged one month and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.
...
- Associated Conditions
- Cystic Fibrosis (CF)
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.